Table 5.
AZD1446 predicted pharmacokinetic parameters
| Treatment group | Number | tmax, pred (h) | Css, max pred (nmol/L) | AUCss, pred (nmol*h/L) | t1/2pred (h) |
|---|---|---|---|---|---|
| Nicotine non-users | |||||
| 10 mg tid | 28 | 0.63 (0.48–2.18) | 196 (21) | 2,120 (21) | 2.11 (11) |
| 80 mg qd | 27 | 0.76 (0.18–6.24) | 1,240 (44) | 5,710 (19) | 2.12 (7.1) |
| 80 mg tid | 31 | 0.82 (0.52–2.70) | 1,460 (36) | 17,600 (28) | 2.11 (11) |
| Nicotine users | |||||
| 80 mg qd | 19 | 0.76 (0.63–2.58) | 1,360 (29) | 5,730 (19) | 2.09 (8.8) |
| 80 mg tid | 17 | 0.74 (0.64–2.49) | 1,440 (27) | 17,000 (17) | 2.05 (11) |
Results are presented as geometric mean (CV%), except for tmax, pred which is presented as median
Css, max pred predicted maximal plasma concentration at steady-state, tmax, pred predicted time to Css, max, AUCss, pred predicted area under the plasma concentration vs. time curve at steady-state, t1/2pred predicted half-life